Christopher Ryan: Drug manufacture of glycomic based molecules at a startup


Image for Christopher Ryan: Drug manufacture of glycomic based molecules at a startup

p.p1 {margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px 'Helvetica Neue'; color: #454545}
The Fall 2017 Biology Seminar Series concludes with Christopher Ryan’s talk, "Drug manufacture of glycomic based molecules at a startup."

p.p1 {margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px 'Helvetica Neue'; color: #454545}

BIOLOGY SEMINARS | FALL 2017

 

Christopher Ryan

Synedgen, Inc.

 

Drug manufacture of glycomic based molecules at a startup

 

The study of glycomics has trailed both genomics and proteomics due to numerous analytical and synthesis challenges. The development of new glycomics tools, the findings that glycosylation of many protein therapeutics increases drug efficacy, and the approval of several glycan drugs have encouraged drug developers to seek out glycomic focused treatments. Glycans are currently used for treatment of diabetes, epilepsy, bacterial infections, and viral infections. Synedgen has developed a platform of polysaccharide derivatives that suppress inflammation, reduce infection, and improve healing. The application of these to model systems has resulted in clinical trials requiring the production of well controlled drugs. The production of polysaccharide drug substances that meet regulatory requirements for good manufacturing practices poses tremendous technical and scientific challenges. These challenges provide unique opportunities to use hypothesis driven science in the manufacturing space to generate new techniques creating a greater barrier to competition.    

 

Tuesday, November 28th

BioScience 113

11:45 a.m.

p.p1 {margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px 'Helvetica Neue'; color: #454545}
p.p2 {margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px 'Helvetica Neue'; color: #454545; min-height: 14.0px}

Email oasin@oxy.edu to sign up for lunch with the speaker after the seminar!